Gut feeling: randomized controlled trials of probiotics for the treatment of clinical depression: Systematic review and meta-analysis

Abstract

Background: Recently the gut microbiota has attracted significant interest in psychiatric research due to the observed bidirectional gut–brain communication. A growing body of evidence from preclinical work has suggested that probiotics may be effective in reducing stress and anxiety and alleviating low mood. It is unclear to what extent these effects are seen in clinical populations. We aimed to identify all published evidence on the efficacy of probiotics as treatment for depression in clinically depressed populations. Methods: Randomized controlled trials of patients with depression where probiotics were used as supplementary or standalone treatment were considered eligible. A literature search with the terms ( probiotic* OR bacteria OR Lactobacillus OR Bifidobacterium) AND depress* was performed in PubMed and Web of Science. Data on study population characteristics, treatment effectiveness, tolerability and risk of bias were extracted from eligible studies. A random effects model was used for meta-analyses. Results: Only three studies met inclusion criteria (229 individuals randomized), two of which administered probiotics as a supplementary treatment to antidepressants and one as a standalone treatment. Upon removal of the latter study from the meta-analysis due to clinical heterogeneity, there was an overall positive effect of probiotics on depressive symptoms (standardized mean difference = 1.371, 95% confidence interval 0.130–2.613). Conclusions: There is limited evidence for the efficacy of probiotics in depression at present, although there may be a beneficial effect of probiotics on depressive symptoms when administered in addition to antidepressants. Further studies are required to investigate this and explore potential mechanisms.

Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer

“…However, evidence is limited due to the heterogeneity of clinical trials. Therefore, further well-designed longitudinal placebo-controlled studies are desperately needed (271,272).…”

“Tobacco Is the Chief Medicinal Plant in My Work”: Therapeutic Uses of Tobacco in Peruvian Amazonian Medicine Exemplified by the Work of a Maestro Tabaquero

“…The description is in line with the scientific understanding of the gut-brain axis, a close relationship between gut health and brain functioning, whereby alterations in gut microbiota may influence psychological health ( Mayer, 2011 ; Foster and McVey Neufeld, 2013 ; Mayer et al, 2015 ). Emerging therapies based on this relatively recent understanding are testing for instance probiotics to treat clinical depression ( Nikolova et al, 2019 ). Beyond its direct action in the neurosystem, nicotine is also known to alter the gut microbiome ( Chi et al, 2017 ) and tobacco’s antiparasitic properties in general are well-documented ( Schorderet Weber et al, 2019 ).…”

Lactobacillus Rhamnosus GG Affects the BDNF System in Brain Samples of Wistar Rats with Pepsin-Trypsin-Digested Gliadin (PTG)-Induced Enteropathy

“…Increasing evidence shows that the gut microbiota can influence the development and maintenance of the CNS and enteric nervous system (ENS), through microbial metabolites, such as short-chain fatty acids and neurotransmitters, able to cross the intestinal and blood-brain barriers [41]. The effectiveness of probiotic supplementation in the reduction of psychological symptoms [42,43] and as an alternative treatment for CD [25] are nowadays the objects of investigation. Indeed, recent results from clinical trials [44], animal models [45], and in vitro studies [46] indicate that the Lactobacillus administration up-regulates BDNF expression.…”